Research Funding & Partners

JOHNSON LABORATORY AT THE JOHNS HOPKINS WILMER EYE INSTITUTE

Funding

The Johnson Laboratory is deeply grateful to the institutions, agencies, foundations and individuals that have provided research funding to enable our work.

Support the Johnson Laboratory

In the quest to develop new diagnostic and therapeutic approaches to preventing and reversing vision loss in glaucoma

To learn more about opportunities to support the Johnson Laboratory through a charitable donation, please contact Kathy Anglemyer at kanglemyer@jhu.edu or click on the button below.

The National Eye Institute, National Institutes of Health (NIH)

  • K08-EY031801 (2020-25)
  • R13-EY034018 (2022)
  • R21-EY034332 (2022-24)
  • R21-EY034677 (2023-35)
  • R44-EY033565 (2022-24)
  • P30-EY001765

Research To Prevent Blindness (RBP, New York, NY)

  • Clinician Scientist Development Award (2020-24)
  • Unrestricted Funding to the Wilmer Eye Institute

The BrightFocus Foundation

  • G20220055 (National Glaucoma Research Award, 2022-24)

The Glaucoma Foundation (TGF)

  • The Rajen Savjani Grant Award (2023-24)

The American Glaucoma Society (AGS)

  • Mentoring for the Advancement of Physician Scientists (MAPS, 2020)
  • Young Clinician Scientist Award (2021-22)

The Association for Research in Vision and Ophthalmology (ARVO)

  • The David L Epstein Award (2019-20)

The Zenkel Family Foundation

The Shelley and Alan Holt Rising Professorship in Ophthalmology

We are grateful for research support from our industry partners, who are helping us identify better ways to care for patients with glaucoma

FireCyte Therapeutics

Working with us to identify novel biomarkers that predict the risk of glaucoma progression.

iCare USA

Providing support to study how fluctuations in eye pressure throughout the day and night may contribute to the risk of vision loss in glaucoma.

Alcon Laboratories

Providing support to understand how the Hydrus Microstent affects intraocular pressure fluctuations throughout the day and night, and to determine real-world outcomes of Hydrus Microstent implantation in patients with glaucoma.

Injectsense

Working with us to develop a new implantable ultra-miniature pressure sensor capable of monitoring patients’ eye pressures continuously for 24 hours a day.